Skip to main content

Pre-Clinical

Pre-Clinical

Modifi Biosciences

Manifest Technologies, Inc.

Small molecule Wnt inhibition: First-in-class therapy for atherosclerosis

A new version of CAR with improved antigen sensitivity

Translura: Mapping the New "Dark Matter" of Genomes

Engineering Beta Cells for Resistance to Immune Attack and Reversal of Diabetes

Extended Release Latanoprost Wafer for the Treatment of Glaucoma

Epiregulin Inhibition to Treat Scleroderma Skin and Lung Fibrosis

ReImmune: A Disposable Bed-Side Device for T cell Immunotherapy without Genetic Engineering

To Identify a New Class of Therapeutics for Inflammatory Diseases

Subscribe to Pre-Clinical